MIF and cancer: As an antagonist of PRG in the PRG-nPR signaling cascade, MIF certainly earned its candidacy early on as an initial therapeutic agent for the treatment of reproductive (breast, prostate, ovarian, endometrial) cancers and endometriosis, and is still on many active clinical trials [82,83,84,85].